JAK2
Driver mutation in myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, myelofibrosis). Targeted by ruxolitinib, fedratinib.
No Drugs found for this biomarker.
Driver mutation in myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, myelofibrosis). Targeted by ruxolitinib, fedratinib.
No Drugs found for this biomarker.